Pascal Biosciences Inc
XTSX:PAS
Pascal Biosciences Inc
Total Current Liabilities
Pascal Biosciences Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pascal Biosciences Inc
XTSX:PAS
|
Total Current Liabilities
CA$851.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Current Liabilities
CA$2.3m
|
CAGR 3-Years
54%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Current Liabilities
$93.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
24%
|
CAGR 10-Years
39%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Current Liabilities
$38.3m
|
CAGR 3-Years
35%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Current Liabilities
CA$3.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Current Liabilities
$32m
|
CAGR 3-Years
84%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pascal Biosciences Inc
Glance View
Pascal Biosciences, Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2012-03-16. The firm is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system. The firm operates in the segment of biotechnology research and development. The firm is focused on developing cannabinoid-based and targeted therapeutics to fight cancer. Its cannabinoid portfolio includes PAS-403, PAS-393 and Cannabinoid for corona virus disease-2019 (COVID-19). Its PAS-403 is a small molecule therapeutics for the treatment of glioblastoma. Its PAS-393, is an immune-stimulatory cannabinoid used in combination with checkpoint inhibitor therapy to treat multiple cancers. In addition, it is developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas.
See Also
What is Pascal Biosciences Inc's Total Current Liabilities?
Total Current Liabilities
851.2k
CAD
Based on the financial report for Nov 30, 2022, Pascal Biosciences Inc's Total Current Liabilities amounts to 851.2k CAD.
What is Pascal Biosciences Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 1Y
32%
Over the last year, the Total Current Liabilities growth was 32%.
